Trial Profile
A Study Investigating the Efficacy and Safety of Apatinib (Rivoceranib) in the Treatment of Patients with Chemotherapy-Resistant Alpha-Fetoprotein Positive Gastric Cancer (AFPGC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.